Lexaria Bioscience (LEXX) Return on Sales (2017 - 2026)
Lexaria Bioscience (LEXX) posted Return on Sales of 0.4% for Q2 2026, up 45.15% sequentially from 0.73% in Q1 2026, and down 18.0% YoY from 0.49% in Q2 2025.
Lexaria Bioscience (LEXX) Return on Sales (2017 - 2026) Analysis & Trends
Lexaria Bioscience has reported Return on Sales for 10 years, with the latest figure at 0.4% in Q2 2026.
- Quarterly Return on Sales fell 18.0% year-over-year to 0.4% in Q2 2026, while the trailing twelve-month figure through May 2026 was 0.4% (down 21.0% YoY) and the FY2025 annual result came in at 0.36%, changed 0.0% from the prior year.
- Return on Sales grew to 0.4% in Q2 2026 per LEXX's latest filing, from 0.73% in the prior quarter.
- Over five years, Return on Sales peaked at 0.07% in Q3 2022 and troughed at 0.73% in Q1 2026.
- A 5-year average of 0.28% and a median of 0.23% in 2025 frame the typical range for Return on Sales.
- The sharpest annual moves came in 2022 and 2026: Return on Sales surged 133 bps in 2022, then tumbled 57 bps in 2026.
- Over 5 years, Return on Sales stood at 0.18% in 2022, then surged by 56 bps to 0.08% in 2023, then sank by 89 bps to 0.15% in 2024, then sank by 40 bps to 0.21% in 2025, then plunged by 93 bps to 0.4% in 2026.
- According to Business Quant data, Return on Sales over the past three periods registered 0.4%, 0.73%, and 0.21% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.93 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.59 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 0.00% |
| 4 | Moderna | 58.86 Bn | 53.73 Bn | 52.00 Mn | -0.05% |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.42 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.19 Bn | 9.80 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 0.00% |
| 10 | Lexaria Bioscience | 10.31 Mn | 6.70 Mn | - | -0.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -0.40% |
| Feb 28, 2026 | -0.73% |
| Nov 30, 2025 | -0.21% |
| Aug 31, 2025 | -0.15% |
| May 31, 2025 | -0.22% |
| Feb 28, 2025 | -0.16% |
| Nov 30, 2024 | -0.15% |
| Aug 31, 2024 | -0.26% |
| May 31, 2024 | -0.32% |
| Feb 29, 2024 | -0.07% |
| Nov 30, 2023 | -0.08% |
| Aug 31, 2023 | -0.36% |
| May 31, 2023 | -0.31% |
| Feb 28, 2023 | -0.68% |
| Nov 30, 2022 | -0.18% |
| Aug 31, 2022 | -0.07% |
| May 31, 2022 | -0.25% |
| Feb 28, 2022 | -0.50% |
| Nov 30, 2021 | -1.51% |
| Aug 31, 2021 | 0.00% |